Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's shift from commissioning to early utilization at its Galesburg facility. With commercial production now underway across its Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein lines, Burcon is seeing increasing customer traction that positions it for better fixed-cost absorption as volume builds.
In the fourth quarter of fiscal 2026, Burcon reported revenue of $0.83 million, up sequentially from $0.74 million in the third quarter. Management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on April and May activity. The company also set a new production record, with daily output roughly 60% above January through March levels. As volume continues to ramp, the margin opportunity is expected to come from better utilization, a steadier production cadence, and the removal of start-up costs from the run-rate cost structure, rather than from pricing alone.
Customer engagement is broadening, with more than 30 purchasing customers and over 200 active projects spanning pea, canola, and fava protein applications. This diversification across multiple protein sources supports Burcon's strategy to capture demand in the growing plant-based protein market. Funding for the Galesburg scale-up is in place, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million of calendar year 2026 sales.
The full announcement, including downloadable images and bios, is available here. For more information on Stonegate Capital Partners, visit their website at Stonegate, Inc..
